Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.

What symbol and exchange does Macrogenics shares trade?

Macrogenics trades on the NASDAQ stock market under the symbol MGNX.

What is Macrogenics stock price doing today?

As of November 10, 2026, MGNX stock price climbed to $2.36 with 110,352 million shares trading.

What is Macrogenics's Beta?

MGNX has a beta of 0.82, meaning it tends to be less sensitive to market movements. MGNX has a correlation of 0.01 to the broad based SPY ETF.

How much is Macrogenics worth?

MGNX has a market cap of $150.33 million. This is considered a Micro Cap stock.

How much money does Macrogenics make?

Last quarter Macrogenics reported $33 million in Revenue and -$.27 earnings per share. This fell short of revenue expectation by $-23 million and missed earnings estimates by -$.41.

What is the highest and lowest price Macrogenics traded in the last 3 year period?

In the last 3 years, MGNX traded as high as $21.88 and as low as $.99.

What are the top ETFs holding Macrogenics?

The top ETF exchange traded funds that MGNX belongs to (by Net Assets): VTI, IWM, VXF, VTWO, IWO.

Is Macrogenics (MGNX) a good investment?

MGNX has outperformed the market in the last year with a price return of +72.3% while the SPY ETF gained +12.3%. However, in the short term, MGNX had mixed performance relative to the market. It has underperformed in the last 3 months, returning -41.6% vs -3.3% return in SPY. But in the last 2 weeks, MGNX shares have fared better than the market returning +7.8% compared to SPY -2.5%.

What are the support and resistance levels for Macrogenics (MGNX)?

MGNX support price is $2.19 and resistance is $2.49 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MGNX shares will trade within this expected range on the day.